Vaxcyte FY2025 EPS Estimate Reduced by Cantor Fitzgerald

Vaxcyte, Inc. (NASDAQ:PCVX) – Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Vaxcyte in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst C. Gould now forecasts that the company will post earnings per share of ($5.50) for the year, down from their previous estimate of ($5.10). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. Cantor Fitzgerald also issued estimates for Vaxcyte’s FY2026 earnings at ($7.28) EPS.

Separately, Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research note on Thursday. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $136.50.

Vaxcyte Trading Down 0.8%

Shares of PCVX opened at $29.67 on Monday. Vaxcyte has a 12-month low of $27.66 and a 12-month high of $121.06. The business’s 50 day moving average is $34.32 and its 200 day moving average is $47.71. The company has a market capitalization of $3.85 billion, a PE ratio of -7.22 and a beta of 1.21.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the prior year, the company earned ($1.10) earnings per share.

Institutional Trading of Vaxcyte

A number of large investors have recently added to or reduced their stakes in PCVX. National Bank of Canada FI purchased a new position in shares of Vaxcyte in the 4th quarter worth approximately $41,000. AlphaQuest LLC purchased a new position in shares of Vaxcyte in the 1st quarter worth approximately $33,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Vaxcyte in the 1st quarter worth approximately $35,000. Parallel Advisors LLC boosted its holdings in shares of Vaxcyte by 203.6% in the 1st quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock worth $61,000 after purchasing an additional 1,071 shares during the period. Finally, IFP Advisors Inc boosted its holdings in shares of Vaxcyte by 376.4% in the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock worth $62,000 after purchasing an additional 1,306 shares during the period. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.